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The urinary bladder is built to perform its functions
of accommodating and emptying urine in a con-
trolled and coordinated way. These performances rely
on sophisticated regulation by the central and periph-
eral nervous systems. When after neurogenic insults,
e.g. trauma, spinal cord injury, or systemic disease
likes multiple sclerosis, the urinary bladder presents a
malfunction in its functions, it is called neurogenic
bladder.
Symptoms of neurogenic bladder vary from detrusor
hypoactivity to overactivity, depending on the site of
neurologic insult. The sphincter at the bladder outlet
may also be involved, resulting in sphincter hypoac-
tivity or overactivity and loss of coordination with
bladder activity.
Injuries of the spinal cord between the pons and
the sacral segment contribute to spastic bladder or
overactive bladder. The bladder usually empties too
quickly and too frequently. Patients with this lesion
may experience urge incontinence. When both the
urinary bladder and external sphincter contract simul-
taneously, the affected individual will feel an extreme
desire to void but only a small amount of urine may
dribble out, and this is described as detrusor-sphincter
dyssynergia.
Voiding dysfunction with urinary incontinence is
one of the most challenging consequences of spinal
cord injury. Among the different types of complication
in the neurogenic bladder, uncontrollable increase in
intravesical pressure is the major cause of injury to the
upper urinary tracts, which usually results in reflux
uropathy and deterioration of renal function.1 Both
detrusor hyperreflexia and detrusor-sphincter dyssyner-
gia may result in the elevation of intravesical pressure.
For decades, efforts have been made to explore new
medical treatments for neurogenic bladder based on
new understandings in pharmacology.
The relationship of adenosine triphosphate (ATP)
and bladder function can be traced back to 1972,
when Burnstock et al first postulated that ATP could
act as an excitatory co-transmitter with acetylcholine
in parasympathetic nerves supplying the urinary blad-
der.2 ATP could be produced and released from the
urothelium in response to mechanical stretch, and
stimulation in interstitial cystitis and bladder outlet
obstruction.3,4 These findings precipitated the discov-
ery of purinergic receptors on the bladder mucosa. It
was later shown that ATP response is mediated via
ligand-gated cation channels, P2X receptors.5 So far,
there have been 7 subtypes of P2X receptors cloned
and characterized in the P2X receptor family.6 The
bladder afferent cells in the L6–S1 dorsal root gan-
glion express chiefly P2X2/3 heteromeric receptors.7
Increased expressions of these purinergic receptors in
the urothelium have been found in several bladder
conditions such as idiopathic detrusor instability,8
neurogenic detrusor overactivity, interstitial cystitis9
and bladder outlet obstruction. Evidence suggests
that P2X receptors serve a combined function in sen-
sory and motor activity of the human bladder. P2X
receptors mediate excitation of sensory neurons and
evoke muscle contraction in response to ATP release.
The purinergic receptors have also been proven to
activate the afferent C-fibers. Many studies have
aimed at better understanding these unique receptors
and have helped to explore many newer purinergic
receptor antagonists in the treatment of overactive
bladder and non-voiding contraction, and the results
seem promising in terms of more efficiency and less
irritation to the bladder compared to intravesical
treatment with conventional agents. Therefore, treat-
ment with purinergic antagonist in these bladder
conditions might provide a novel therapy for patients
refractory to conventional antimuscarinic therapy.
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Spinal cord injury results in changes in pharmaco-
logic and morphologic properties of urothelium and
bladder afferent neurons. In this situation, ATP is
released from the urothelium upon both mechanical
and chemical stimulations. Through the purinergic
receptors present in the C-fiber afferents, ATP can
trigger a reflex bladder activity.
In this issue of the Journal of the Chinese Medical
Association, Lu and colleagues10 evaluate the effects of
a selective non-nucleotide P2X3 and P2X2/3 purinergic
receptor antagonist A-317491 (5-((3-phenoxybenzyl)
[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] amino car-
bonyl)-1,2,4-benzenetricarboxylic acid) on the non-
voiding contraction and voiding detrusor contractility
of bladder in a rat model of spinal cord transection 
at the T8–T9 segmental level. A-317491 has been
shown to be a good blocker of peripheral P2X recep-
tors due to its ability to completely block the afferent
activation and mechanical sensitization induced by P2X
agonists.11,12 In Lu et al’s study, A-317491 was given
intravesically in a series of escalating doses to rats 14–16
weeks after spinal transection, and cystometrograms
were recorded before and after each drug administra-
tion. The investigators found that A-317491 at doses
between 1 and 30µmol/kg significantly prolonged the
interval between voids and reduced the number of
non-voiding contractions, and increased the pressure
threshold for voiding. The effects appeared within 10
minutes of drug administration. However, they found
that this drug failed to change the amplitude or the
duration of the voiding contractions. These findings
indicate that the mechanism via purinergic receptors
P2X3 or P2X2/3 may contribute to the detrusor hyper-
reflexia that occurs after spinal cord injury. Therefore,
A-317491 may be considered a promising option to
treat detrusor overactivity in neurogenic bladder dis-
orders if efficacy and safety issues are validated in further
clinical trials.
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